Literature DB >> 7850709

Cellular schwannoma. A clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients.

G P Casadei1, B W Scheithauer, T Hirose, M Manfrini, C Van Houton, M B Wood.   

Abstract

BACKGROUND: A clinicopathologic study of 70 cases of cellular schwannoma was performed to assess their distribution, response to therapy, and rate of recurrence relative to modern prognostic indicators.
METHODS: Seventy-one cellular schwannomas from 70 patients were retrieved from the files of the Mayo Clinic Tissue Registry. The significance of mitotic index, proliferative marker staining (proliferating cell nuclear antigen and MIB1), immunochemical p53 expression, and DNA ploidy were assessed relative to tumor behavior, particularly recurrence. All parameters were subject to statistical analysis (Student's t test).
RESULTS: Cellular schwannomas represented 4.6% of benign peripheral nerve tumors operated on at the Mayo Clinic. In 15% of the cases, an initial diagnosis of malignancy had been made. The median patient age was 47.7 years (range, 15-80 years) and the female-to-male ratio was 1.6:1. The principle tumor locations were the para- and intraspinal regions, including the sacrum (64%), extremities (25%), and intracranial space (8%). All tumors consisted primarily of hypercellular, compact, Antoni A tissue. Mitoses (< or = 4/10 hPF]) were observed in 71% of the cases. Foci of necrosis were noted in 11% of cases. Ultrastructural studies and immunohistochemistry clearly demonstrated features of schwannian differentiation. Surgery was the treatment in all cases. Excision was intralesional to gross total in the majority; total resection with wide margins was undertaken in three tumors, each of which had initially been considered malignant. Follow-up in 47 patients (67%) ranged from 1 to 29 years (mean, 7.7 years) and revealed recurrences in 11 patients (23.4%): no patient experienced metastasis or died of tumor. Although no correlation existed between recurrence and DNA ploidy, percent S-phase determinations, proliferation marker (PCNA, MIB1) staining, or the frequency of p53 immunoreactivity, a statistically significant correlation (P < 0.001) was observed, however, between recurrence and mitotic indices.
CONCLUSION: Proliferation indices, as defined by immunochemical analysis, are not useful predictors of recurrence in cellular schwannoma. In lesions not completely resected, tumor recurrence is significantly correlated with mitotic count. The significant overall frequency of recurrence in this series is attributable to a high proportion of intraspinal and intracranial tumors. Our study confirms the benign nature of cellular schwannoma and underscores the necessity of distinguishing them from malignant peripheral nerve sheath tumors, lesions that often require adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850709     DOI: 10.1002/1097-0142(19950301)75:5<1109::aid-cncr2820750510>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

Review 2.  Neuropathology for the neuroradiologist: palisades and pseudopalisades.

Authors:  F J Wippold; M Lämmle; F Anatelli; J Lennerz; A Perry
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

3.  A recurrent cellular schwannoma.

Authors:  Eung Re Kim; Eun Oh Choi; Kyung Bun Lee; Chang Hyun Kang; Young Tae Kim; In Kyu Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-10-05

4.  [Low-malignant peripheral nerve sheath tumors of nasal and sinonasal mucous membranes].

Authors:  K Katenkamp; D Katenkamp
Journal:  Pathologe       Date:  2005-03       Impact factor: 1.011

5.  Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.

Authors:  Melike Pekmezci; David E Reuss; Angela C Hirbe; Sonika Dahiya; David H Gutmann; Andreas von Deimling; Andrew E Horvai; Arie Perry
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

Review 6.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Authors:  Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry
Journal:  Hum Pathol       Date:  2017-05-24       Impact factor: 3.466

7.  Intracranial cellular schwannomas: a clinicopathological study of 20 cases.

Authors:  Felipe D'Almeida Costa; Tiago M Dias; Kara A Lombardo; Aditya Raghunathan; Caterina Giannini; Lawrence Kenyon; Ali G Saad; Murat Gokden; Peter C Burger; Elizabeth A Montgomery; Fausto J Rodriguez
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

Review 8.  Bowel mesentery (meso-appendix) microcystic/reticular schwannoma: case report and literature review.

Authors:  Shao-Xian Tang; Yi-Hua Sun; Xian-Rong Zhou; Jian Wang
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

9.  Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.

Authors:  L G Kindblom; M Ahldén; J M Meis-Kindblom; G Stenman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Cellular schwannoma masquerading as malignant peripheral nerve sheath tumour: a diagnostic dilemma.

Authors:  Kiran Alam; Anshu Jain; Aroonima Misra; A H Khan
Journal:  BMJ Case Rep       Date:  2013-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.